Lantheus (NASDAQ:LNTH) Issues FY 2024 Earnings Guidance

Lantheus (NASDAQ:LNTH) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 6.650-6.700 for the period, compared to the consensus EPS estimate of 6.750. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Analysts Set New Price Targets

Several analysts recently issued reports on LNTH shares. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. JMP Securities reissued a “market outperform” rating and issued a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. The Goldman Sachs Group started coverage on Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. Finally, Truist Financial reissued a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Price Performance

Shares of LNTH opened at $91.13 on Wednesday. Lantheus has a one year low of $51.79 and a one year high of $126.89. The company has a 50-day simple moving average of $91.78 and a two-hundred day simple moving average of $100.12. The firm has a market capitalization of $6.34 billion, a PE ratio of 15.16 and a beta of 0.46.

Insiders Place Their Bets

In other news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the completion of the transaction, the director now directly owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.50% of the stock is currently owned by company insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.